Uromune

Last updated

Uromune
Vaccine description
TargetBacteria ( E. coli , K. pneumoniae , E. faecalis , P. vulgaris )
Vaccine type Inactivated
Clinical data
Trade names Uromune
Other namesMV-140; MV140
Routes of
administration 		Sublingual spray
ATC code
  • None

Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs). [1] [2] [3] In clinical studies, it has been found to reduce total number of UTIs by about 70%, to increase UTI-free rates from around 25% to 57%, and to increase time to next UTI from about 1.6 months to 9.0 months. [2] [4] [5] [6] It has also been found to reduce subjective UTI symptoms, reduce antibiotic use, and improve quality of life. [2] [4] [5] [6] The effectiveness of the vaccine appears to decrease with time, which might warrant readministration. [2] [5] [6] [7] Uromune is used as a sublingual spray once daily for 3 months. [2] [3] [5]

Contents

Side effects of Uromune are considered infrequent, minor, and usually not treatment-related. [2] Uromune is an inactivated combination of four major bacteria known to cause recurrent UTIs, including Escherichia coli , Klebsiella pneumoniae , Enterococcus faecalis , and Proteus vulgaris . [2] It is thought to work by increasing adaptive immunity against UTI-causing bacteria. [2] [8] It might also work by increasing trained immunity against these pathogens. [2] [8]

Uromune first became available for clinical use in 2010 [2] and was first described in the literature by 2012. [9] It was developed and marketed in Spain by Inmunotek S.L. [1] [10] [9] Uromune has also been approved in Mexico and the Dominican Republic and is currently pending approval in Canada. [2] [11] [1] The vaccine is under development for use and is available via special-access programs in numerous other countries, including in many European countries, Australia, New Zealand, and Chile, among others. [1] [2] [11] Development and approval in the United States is in progress but is expected to take longer than in other countries. [6] [11] Uromune is also under investigation for other uses besides prevention of uncomplicated recurrent UTIs in adults. [2] In addition, readministration of the vaccine following potential waning effectiveness is being studied. [2]

Medical uses

Recurrent urinary tract infections

Uromune is used in the prevention of uncomplicated recurrent UTIs in adults. [2] It is indicated specifically for prevention of recurrent UTIs, defined as ≥3 UTIs in 12 months or ≥2 UTIs within 6 months. [5] [3] The vaccine has been described as highly effective against recurrent UTIs. [10] Uromune is a suspension of selected strains of several whole-cell, heat-killed bacteria, including V121 Escherichia coli (25%), V113 Klebsiella pneumoniae (25%), V125 Enterococcus faecalis (25%), and V127 Proteus vulgaris (25%), in glycerol, sodium chloride, artificial pineapple flavoring, and water. [2] [3] These bacteria together are responsible for most cases of UTIs, with E. coli alone responsible for 52 to 80% of recurrent UTIs. [5] [3] [4] Uromune is thought to increase immunity against these UTI-causing bacteria. [2] The vaccine is self-administered as a sublingual spray with two sprays of 100 μL each given once daily for 3 months. [2] [3] [5]

A European phase 3 clinical trial, with results published in 2021 and 2022, found that median 0.0 (IQR Tooltip interquartile range 0.0–1.0) UTIs occurred with Uromune and median 3.0 UTIs (IQR 0.5–6.0) occurred with placebo during 9 months following a 3- to 6-month Uromune treatment period in 240 women. [2] [12] [4] [13] There were a total of 249 UTIs with placebo, 80 UTIs with 3-month Uromune (−68% relative to placebo), and 70 UTIs (−72% relative to placebo) with 6-month Uromune during the 9-month period. [4] The 9-month UTI-free rate was 55.7% with 3 months of Uromune treatment and 58.0% with 6 months of Uromune treatment versus 25.0% with placebo. [2] [12] Hence, the UTI-free rate was more than doubled with Uromune in this trial (increased by ~2.3-fold). [2] [12] The median time to first UTI after treatment was 275.0 days with both 3-month and 6-month Uromune relative to 48.0 days with placebo. [2] In subanalyses of the trial, Uromune reduced overall UTI symptoms, resulted in fewer days on antibiotics, and improved total, general, and physical quality of life. [2]

A 2020 systematic review identified three clinical studies of Uromune, including a prospective cohort study, a retrospective cohort study, and a retrospective observational study, all conducted in the United Kingdom or Spain. [5] For short-term efficacy (≤6 months), the UTI-free rate with Uromune was 63.5 to 81%, relative to 3 to 5.6% for antibiotic therapy. [5] For long-term efficacy (>6 months), the UTI-free rate was 56.6% and 90.3%, with the longest reported outcome being 56.6% at 15 months, whereas almost all patients given daily antibiotic therapy had experienced at least one UTI by 12 and 15 months. [5] UTI recurrence occurred at median 180 days with Uromune and median 19 days with antibiotic prophylaxis. [5] A subsequent 2023 review of five observational studies with over 1,400 women, including the above studies, reported that Uromune was associated with higher UTI-free rates (35–58%) relative to 6-month antibiotic prophylaxis (0%) in two comparative observational studies and was associated with UTI-free rates of 33 to 78% over 9 to 24 months of follow-up in three uncontrolled prospective observational studies. [2] [3] Likewise, in the five observational studies with 1,408 women, another 2020 systematic review reported UTI-free rates of 35 to 90% with Uromune in 519 women versus rates of 0–9% with antibiotic prophylaxis in 499 women over 15 months. [3] [12]

In a preliminary analysis of the Health Canada-approved first-in-North America observational study, findings were comparable to previous observational studies. [2] In this study, which included 25 patients, the UTI rate was reduced by 82% for the 9-month post-vaccination period, with number of UTIs reducing from mean 11.5 UTIs/month to 2.1 UTIs/month, and the UTI-free rate during this period was 48% (12 of 25). [2] At 12 months, 80% of subjects (20 of 25) reported that they were moderately or markedly improved. [2] The preceding results are from the pre-COVID-19 pandemic cohort and an expanded follow-up with 64 women has been conducted with results published. [2] [14] [15] [16] In the expanded cohort, there were a mean of 6.8 UTIs/year pre-vaccination, the UTI-free rate over the 9-month post-vaccination period was 40.6%, the reduction of infection rate was 75.3% for this period relative to the year prior to vaccination, and 80.3% reported being moderately or markedly improved at 12-month follow-up, with 58.1% considering themselves "mostly satisfied, pleased, or delighted". [14] [15] [16] Quality of life scored also improved by 1.5 points in the study. [14]

The risk of UTI recurrence with Uromune treatment has been found to increase with time, suggesting that the vaccine gradually wears off. [5] [6] In a 2022 long-term prospective observational study with 1,003 patients, Uromune reduced the number of UTIs to 0–2 in 95.5% at 3 months, in 86.8% at 6 months, and in 54.7% at 12 months. [7] On the basis of these findings, readministration may be warranted and may be studied in the future. [5] [6] [7] [2] However, in a 2024 study that was the first long-term study of Uromune, where 60% of individuals had a single course of Uromune and 40% had repeat courses 1 to 2 years after the first course, 54% of 89 women and men remained UTI-free 5 to 9 years after first receiving the vaccine. [17]

As of May 2023, at least eight clinical studies of Uromune, including one phase 3 randomized controlled trial, have been conducted. [2] [11] [6] These studies have included over 2,200 patients. [2] More than 40,000 patients have received Uromune as of 2023, including at least 22,000 in special-access programs. [18] [2] [11] [6]

Side effects

Side effects of Uromune are reported to be infrequent and minor. [2] In two comparative studies of Uromune versus antibiotics, no adverse reactions were reported with Uromune. [2] In the United Kingdom prospective study, one serious adverse reaction—an allergic reaction—and seven minor adverse reactions (post-nasal drip, mouth stinging, scar itching, abdomen itching, abdominal pain, mild nausea, and worsening of asthma) were reported. [2] In two other studies of 166 and 784 patients, minor side effects including dry mouth (n=8), gastritis (n=4), general illness (n=3), glossitis (n=2), and flare-up of rheumatoid arthritis not thought to be treatment-related (n=1). [2] In the North American clinical study, there were five non-serious adverse reactions and one serious adverse reaction in 25 individuals, with one mild and self-limited adverse reaction deemed potentially vaccine-related. [2] In safety reports of 22,000 patients receiving the vaccine, there were 15 filed reports of adverse reactions for more than 1.5 million doses. [2]

In the phase 3 randomized controlled trial of Uromune versus placebo, there were 76 adverse reactions in the 3-month Uromune group, 48 adverse reactions in the 6-month Uromune group, and 81 adverse reactions in the placebo group. [2] The most frequent adverse reactions, occurring in ≥5% of individuals, were chest infections, candidiasis, and vaginitis. [2] The seven serious adverse reactions, which occurred in five individuals, were considered related to Uromune. [2] Of the 205 adverse effects reported in the trial, 9 (4.4%), presenting in five individuals (2.2%), were considered to be study intervention-related. [2] This included two in the placebo group (2.6%), three with 3-month Uromune (3.9%), and zero with 6-month Uromune (0.0%). [2] On the basis of these findings, it has been concluded that Uromune may be considered a very safe medical intervention. [2]

In the 2020 systematic review, Uromune was described as having acceptable safety and minimal adverse effects. [5]

Pharmacology

The mechanism of action of Uromune is believed to be induction of antibody production and activation of human dendritic cells to generate T helper (Th) 1, Th17, and interleukin-10, in turn resulting in anti-inflammatory T-cell responses in secondary lymphoid organs and locally in the bladder. [2] [3] [8] It is thought that induction of adaptive immunity following Uromune treatment discontinuation results in lasting clinical protection, although trained immunity may also be involved. [2] Uromune is administered sublingually, which is known to bypass degradation by gastric fluids and gastrointestinal enzymes that occurs with oral administration. [3] Moreover, sublingual administration is thought to have the potential to induce mucosal immune responses in a broad range of tissues, including the genitourinary tract. [3] Accordingly, Uromune has been found to induce immune responses both systemically and in the genitourinary tract. [3]

History

Uromune was first described in the literature by 2012. [9] The vaccine has been available since 2010 in clinical practice. [2] It was developed and marketed in Spain by the pharmaceutical company Inmunotek S.L. in Madrid. [1] [10] [9] The vaccine has also since been approved in Mexico and the Dominican Republic. [2] [11] As of October 2023, Uromune is under development for use in other countries and is in the preregistration phase of development, with approval pending in Canada. [2] [1] It is also available for patients through various special-access (compassionate-use) programs in 26 countries. [1] [11] Countries where Uromune is under development or available through early-access programs include Australia, Belgium, Canada, Chile, the Czech Republic, Denmark, Finland, France, Germany, Luxembourg, the Netherlands, New Zealand, Norway, Portugal, Romania, Serbia, Slovakia, Slovenia, Sweden, Turkey, and the United Kingdom, among others. [1] [2] [11] A notable exception among countries is the United States, where more stringent clinical trials are likely to be required before Uromune could be approved or made available. [6] [11] Moreover, a United States-based randomized controlled trial may be required for approval in this country. [16] Development of Uromune in Canada has been licensed to Red Leaf Medical. [18]

Research

Special populations

Clinical development of Uromune for prevention of UTIs in elderly people in long-term care homes, in children with recurrent UTIs, and in adults with complicated recurrent UTIs (e.g., patients with catheters or neurogenic bladder) is in the tentative planning stages. [2] [19] Further assessment of Uromune may also include repeated administration following potential long-term loss of immunity and possible combination with vaccines for related infections. [2] [20] [21]

Other UTI vaccines

Several other UTI vaccines are also under development. [3] [5] [22] These include OM-89 (OM-8980, UroVaxom; oral tablet), [23] Solco-Urovac (StroVac; vaginal suppository/intramuscular injection), [24] [25] ExPEC4V (V10, JNJ-63871860; intramuscular injection), [26] and SEQ-400 (route unspecified). [27]

See also

Related Research Articles

<span class="mw-page-title-main">Urinary tract infection</span> Infection that affects part of the urinary tract

A urinary tract infection (UTI) is an infection that affects a part of the urinary tract. Lower urinary tract infections may involve the bladder (cystitis) or urethra (urethritis) while upper urinary tract infections affect the kidney (pyelonephritis). Symptoms from a lower urinary tract infection include suprapubic pain, painful urination (dysuria), frequency and urgency of urination despite having an empty bladder. Symptoms of a kidney infection, on the other hand, are more systemic and include fever or flank pain usually in addition to the symptoms of a lower UTI. Rarely, the urine may appear bloody. Symptoms may be vague or non-specific at the extremities of age.

<span class="mw-page-title-main">Mannose</span> Chemical compound

Mannose is a sugar monomer of the aldohexose series of carbohydrates. It is a C-2 epimer of glucose. Mannose is important in human metabolism, especially in the glycosylation of certain proteins. Several congenital disorders of glycosylation are associated with mutations in enzymes involved in mannose metabolism.

<span class="mw-page-title-main">Levofloxacin</span> Antibiotic

Levofloxacin, sold under the brand name Levaquin among others, is a broad-spectrum antibiotic of the fluoroquinolone drug class. It is the left-handed isomer of the medication ofloxacin. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, H. pylori, urinary tract infections, Legionnaires' disease, chronic bacterial prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis, meningitis, or pelvic inflammatory disease. It is available by mouth, intravenously, and in eye drop form.

<span class="mw-page-title-main">Nitrofurantoin</span> Antibacterial drug

Nitrofurantoin, sold under the brand name Macrobid among others, is an antibacterial medication of the nitrofuran class used to treat urinary tract infections (UTIs), although it is not as effective for kidney infections. It is taken by mouth.

<span class="mw-page-title-main">Amoxicillin/clavulanic acid</span> Combination antibiotic medication

Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, sold under the brand name Augmentin, among others, is an antibiotic medication used for the treatment of a number of bacterial infections. It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Pyelonephritis</span> Inflammation of the kidney

Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most often include fever and flank tenderness. Other symptoms may include nausea, burning with urination, and frequent urination. Complications may include pus around the kidney, sepsis, or kidney failure.

Hypogammaglobulinemia is an immune system disorder in which not enough gamma globulins are produced in the blood. This results in a lower antibody count, which impairs the immune system, increasing risk of infection. Hypogammaglobulinemia may result from a variety of primary genetic immune system defects, such as common variable immunodeficiency, or it may be caused by secondary effects such as medication, blood cancer, or poor nutrition, or loss of gamma globulins in urine, as in nonselective glomerular proteinuria. Patients with hypogammaglobulinemia have reduced immune function; important considerations include avoiding use of live vaccines, and take precautionary measures when traveling to regions with endemic disease or poor sanitation such as receiving immunizations, taking antibiotics abroad, drinking only safe or boiled water, arranging appropriate medical cover in advance of travel, and ensuring continuation of any immunoglobulin infusions needed.

<span class="mw-page-title-main">Norfloxacin</span> Chemical compound, antibiotic

Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.

<span class="mw-page-title-main">Cinoxacin</span> Chemical compound

Cinoxacin is a quinolone antibiotic that has been discontinued in the U.K. as well the United States, both as a branded drug or a generic. The marketing authorization of cinoxacin has been suspended throughout the EU.

<span class="mw-page-title-main">Chronic bacterial prostatitis</span> Bacterial infection of the prostate gland

Chronic bacterial prostatitis is a bacterial infection of the prostate gland. It should be distinguished from other forms of prostatitis such as acute bacterial prostatitis and chronic pelvic pain syndrome (CPPS).

<span class="mw-page-title-main">Pivmecillinam</span> Chemical compound

Pivmecillinam (INN), or amdinocillin pivoxil (USAN), sold under the brand name Selexid and Pivya among others, is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic. Pivmecillinam is the pivaloyloxymethyl ester of mecillinam.

<span class="mw-page-title-main">Purple urine bag syndrome</span> Medical condition

Purple urine bag syndrome (PUBS) is a medical syndrome where purple discoloration of urine collection bag occurs in people with urinary catheters and co-existent urinary tract infections. PUBS is most prevalent in elderly females with constipation. Constipation alters the gut bacteria, reducing gastrointestinal motility and leading to increased growth of bacteria in the colon. High bacterial counts in urine are the most important factor causing purple urine bag syndrome. Bacteria in urine produce the enzyme indoxyl sulfatase. This converts indoxyl sulfate in the urine into the red and blue colored compounds indirubin and indigo. People with urinary tract infections using catheters will increase the conversion of indoxyl sulfatase to indirubin and indigo. Indirubin dissolves in plastic and therefore causes urine discoloration. The purple discoloration is the result of reaction between indirubin and plastic urine bags, as well as the presence of indigo. Bacteria in the urine can be found through bacteria culture test. People with purple urine bag syndrome may present with elevated bacterial loads on their culture tests when compared to those who are not affected by this syndrome. The most commonly implicated bacteria are Providencia stuartii, Providencia rettgeri, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli, Morganella morganii, and Pseudomonas aeruginosa. Purple urine bag syndrome treatment should aim for underlying issues rather than the condition itself. The purple discoloration is harmless and can be resolved with treatments targeted to specific bacteria or any underlying medical conditions. Treatment also consists of providing comfort to both patients and their family, administering antibiotics and performing regular catheter changes. The prognosis is good, however, the morbidity and mortality rates associated with PUBS are elevated depending on patient's underlying health status.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

<span class="mw-page-title-main">Cefiderocol</span> Antibiotic

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection.

Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines that are prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual.

<span class="mw-page-title-main">Lactobacillus vaccine</span> Vaccine using an inactivated strain of Lactobacillus

Lactobacillus vaccines are used in the therapy and prophylaxis of non-specific bacterial vaginitis and trichomoniasis. The vaccines consist of specific inactivated strains of Lactobacilli, called "aberrant" strains in the relevant literature dating from the 1980s. These strains were isolated from the vaginal secretions of patients with acute colpitis. The lactobacilli in question are polymorphic, often shortened or coccoid in shape and do not produce an acidic, anti-pathogenic vaginal environment. A colonization with aberrant lactobacilli has been associated with an increased susceptibility to vaginal infections and a high rate of relapse following antimicrobial treatment. Intramuscular administration of inactivated aberrant lactobacilli provokes a humoral immune response. The production of specific antibodies both in serum and in the vaginal secretion has been demonstrated. As a result of the immune stimulation, the abnormal lactobacilli are inhibited, the population of normal, rod-shaped lactobacilli can grow and exert its defense functions against pathogenic microorganisms.

OM-85 or OM85 is an immunostimulant. It is a combination of molecules extracted from the walls of bacteria that commonly cause respiratory infections.

A UTI vaccine is a vaccine used for prevention of recurrent urinary tract infections (UTIs). A number of UTI vaccines have been developed and/or marketed. These include Uromune, UroVaxom, Solco-Urovac, ExPEC4V, and SEQ-400.

<span class="mw-page-title-main">Urinary anti-infective agent</span> Medication for urinary tract infections

Urinary anti-infective agent, also known as urinary antiseptic, is medication that can eliminate microorganisms causing urinary tract infection (UTI). UTI can be categorized into two primary types: cystitis, which refers to lower urinary tract or bladder infection, and pyelonephritis, which indicates upper urinary tract or kidney infection. Escherichia coli is the predominant microbial trigger of UTIs, accounting for 75% to 95% of reported cases. Other pathogens such as Proteus mirabilis, Klebsiella pneumoniae, and Staphylococcus saprophyticus can also cause UTIs.

References

  1. 1 2 3 4 5 6 7 8 "MV 140". Adis Insight. Springer Nature Switzerland AG. Retrieved 15 February 2024.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Nickel JC, Doiron RC (February 2023). "An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women". Pathogens. 12 (3): 359. doi: 10.3390/pathogens12030359 . PMC   10052183 . PMID   36986281.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 Nickel JC, Saz-Leal P, Doiron RC (August 2020). "Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future". Can Urol Assoc J. 14 (8): 281–287. doi:10.5489/cuaj.6690. PMC   7402698 . PMID   33626320.
  4. 1 2 3 4 5 Lorenzo-Gómez MF, Foley S, Nickel JC, García-Cenador MB, Padilla-Fernández BY, González-Casado I, et al. (April 2022). "Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections". NEJM Evid. 1 (4): EVIDoa2100018. doi:10.1056/EVIDoa2100018. PMID   38319200. S2CID   246177950.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Prattley S, Geraghty R, Moore M, Somani BK (May 2020). "Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review". Eur Urol Focus. 6 (3): 593–604. doi:10.1016/j.euf.2019.11.002. PMID   31806578. S2CID   208743752.
  6. 1 2 3 4 5 6 7 8 9 Hart H (September 16, 2021). "Novel vaccine MV140 effective at treating recurrent UTIs". Urology Times. 49 (12).
  7. 1 2 3 Ramírez Sevilla C, Gómez Lanza E, Llopis Manzanera J, Cetina Herrando A, Puyol Pallàs JM (November 2022). "A Focus on Long-Term Follow-Up of Immunoprophylaxis to Recurrent Urinary Tract Infections: 10 Years of Experience with MV140 Vaccine in a Cohort of 1003 Patients Support High Efficacy and Safety". Arch Esp Urol. 75 (9): 753–757. doi:10.56434/j.arch.esp.urol.20227509.110. PMID   36472057. S2CID   254274602.
  8. 1 2 3 Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O (July 2017). "MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88". Mucosal Immunol. 10 (4): 924–935. doi: 10.1038/mi.2016.112 . PMID   27966556.
  9. 1 2 3 4 Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. (January 2013). "Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics". Int Urogynecol J. 24 (1): 127–34. doi:10.1007/s00192-012-1853-5. PMC   3536982 . PMID   22806485.
  10. 1 2 3 Mba IE, Sharndama HC, Anyaegbunam ZK, Anekpo CC, Amadi BC, Morumda D, et al. (April 2023). "Vaccine development for bacterial pathogens: Advances, challenges and prospects". Trop Med Int Health. 28 (4): 275–299. doi:10.1111/tmi.13865. PMID   36861882. Uromune, developed by Inmunotek, a Spanish-based pharmaceutical company, is also currently in phase III clinical trial. This vaccine, Uromune, administered as a spray, has proven to be highly effective against chronic or recurrent UTIs. It contains inactivated E. coli, Proteus vulgaris, K. pneumoniae and Enterococcus faecalis
  11. 1 2 3 4 5 6 7 8 9 "Sublingual Vaccine Shows Efficacy in Preventing Recurrent UTIs, Helping to Eliminate Need for Antibiotics". 25 May 2023. Retrieved 15 February 2024.
  12. 1 2 3 4 Nickel JC, Lorenzo-Gómez MF, Foley S, Saz-Leal P (2021). "PLLBA-02 A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women". Journal of Urology. 206 (Supplement 3). doi:10.1097/JU.0000000000002150.02. ISSN   0022-5347.
  13. ↑ Werneburg GT (2022). "Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects". Res Rep Urol. 14: 109–133. doi: 10.2147/RRU.S273663 . PMC   8992741 . PMID   35402319. MV-140 (Uromune, Syner-Med Ltd UK; Immunotek S.L. Spain), a sublingual spray, has been evaluated for safety and efficacy.128 The MV-140 vaccine is composed of inactivated cell lysates of common uropathogens. Specifically, it contains lysates of E. coli, Klebsiella pneumonia, Proteus vulgaris, and Enterococcus faecalis. In a prospective study that included 77 women with recurrent UTI (each had 3 or more UTI episodes in the preceding 12 months), the vaccine was administered for 3 months, and 78% of the population was UTI-free over the 12-month follow-up period.128 In this study, one patient experienced rash and thus had to stop treatment. The first phase III, randomized, placebo-controlled, double-blind clinical trial was recently reported.129 The trial included 240 women with recurrent UTI, randomized to either MV140 (for 3 or 6 months) or placebo. The median number of UTIs in the 9 months post-vaccination was 3.0 in the placebo compared to 0.0 in the MV-140 treatment groups. There was a greater UTI-free rate in the MV-140 groups. Five subjects reported adverse reactions, all of which were non-serious (3 in the treatment groups, 2 in the placebo group). While these remarkable findings open new prevention avenues for this patient cohort, whether or not they are generalizable to a population with indwelling urethral catheters remains to be determined.
  14. 1 2 3 Nickel JC, Kelly KL, Griffin A, Elterman S, Clark-Pereira J, Doiron RC (February 2024). "MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study". Can Urol Assoc J. 18 (2): 25–31. doi:10.5489/cuaj.8455. PMC   10841562 . PMID   37931282.
  15. 1 2 Hickling D (February 2024). "MV140 sublingual vaccine proves promising in fighting recurrent urinary tract infections in women". Can Urol Assoc J. 18 (2): 32. doi:10.5489/cuaj.8716. PMC   10841568 . PMID   38315548.
  16. 1 2 3 "Vaccine for recurrent UTIs reduces infection rate by 74.8%". www.healio.com.
  17. ↑ Kanabar S, Foley S, Yang B (2024). "Assessing the long-term efficacy and safety of MV140 sublingual bacterial vaccine in the initial cohort: A 9-year study in the UK for treating recurrent urinary tract infections in men and women". European Urology. 85 (Suppl 1): S1037–S1037. doi:10.1016/S0302-2838(24)00833-9.
  18. 1 2 "UROMUNE™ (MV 140)". Red Leaf Medical Inc.
  19. ↑ Kovacic J, Canagasingham A, Zhong W, Lockhart K, Dhar A, Shepherd A, et al. (December 2023). "Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double-blind randomized controlled trial protocol". BJU Int. doi:10.1111/bju.16247. PMID   38060333. S2CID   266147428.
  20. ↑ Martin-Cruz L, Sevilla-Ortega C, Benito-Villalvilla C, Diez-Rivero CM, Sanchez-Ramón S, Subiza JL, et al. (2020). "A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections". Front Immunol. 11: 612269. doi: 10.3389/fimmu.2020.612269 . PMC   7858650 . PMID   33552074.
  21. ↑ Martín-Cruz L, Angelina A, Baydemir I, Bulut Ö, Subiza JL, Netea MG, et al. (2022). "Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections". Front Immunol. 13: 1066383. doi: 10.3389/fimmu.2022.1066383 . PMC   9729253 . PMID   36505433.
  22. ↑ Doiron RC, Cotechini T, Nickel JC (June 2024). "It's Time to Embrace Vaccination as We Enter the Postantibiotic Era of Recurrent Urinary Tract Infection Management". J Urol. 211 (6): 797–799. doi:10.1097/JU.0000000000003969. PMID   38704743.
  23. ↑ "OM 8980". AdisInsight. 16 August 2022. Retrieved 11 October 2024.
  24. ↑ Mak Q, Greig J, Dasgupta P, Malde S, Raison N (April 2024). "Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis". Eur Urol Focus. doi:10.1016/j.euf.2024.04.002. PMID   38644097.
  25. ↑ Litschgi M (February 1987). "Harnwegsinfektbehandlung mit SolcoUrovac" [Treatment of urinary tract infections with SolcoUrovac]. Geburtshilfe Frauenheilkd (in German). 47 (2): 107–110. doi:10.1055/s-2008-1035786. PMID   3106132.
  26. ↑ "JNJ 63871860". AdisInsight. 5 November 2023. Retrieved 11 October 2024.
  27. ↑ "SEQ 400". AdisInsight. 15 September 2023. Retrieved 11 October 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.